The Pharmaceutical Journal
Vol 271 No 7261 p169
9 August 2003

This article
Reprint
Photocopy

News summary

Related websites
MeReC Bulletin (more)

MeReC says role for new topical eczema treatments is limited

Atopic eczema can be controlled in most patients through the avoidance of exacerbating factors, and the use of emollients, topical corticosteroids and, where indicated, oral antibiotics, according to the latest issue of MeReC Bulletin. The topical immunosuppressive agent tacrolimus (Protopic) should be reserved for second-line treatment in certain circumstances (eg, when stronger corticosteroids are needed most of the time or for use on the face). Evidence for pimecrolimus (Elidel) is insufficient, it adds.

The bulletin can be downloaded from the National Prescribing Centre website.